Skip to main content

Advertisement

Log in

Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The human JAK2 gene is mainly targeted by two types of genetic lesions that play roles in the pathogenesis of hematologic malignancies: intragenic mutations and chromosomal translocations. Chromosomal translocations of JAK2 are typically associated with myeloid or lymphoid malignancies with an aggressive course and poor outcome. Here we report a t(9;22)(p24;q11.2) translocation, in a MDS patient and review results associated with BCR-JAK2 fusion reported in the literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Smith CA, Fan G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol. 2008;39(6):795–810.

    Article  CAS  PubMed  Google Scholar 

  2. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma. 2008;49(3):388–97.

    Article  CAS  PubMed  Google Scholar 

  3. Walz C, Cross NC, Van Etten RA, Reiter A. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008;22(7):1320–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Bain BJ, Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol. 2014;166:809–17.

    Article  CAS  PubMed  Google Scholar 

  5. Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer. 2005;44(3):329–33.

    Article  CAS  PubMed  Google Scholar 

  6. Cirmena G, Aliano S, Fugazza G, Bruzzone R, Garuti A, Bocciardi R, et al. A BCR-JAK2 fusion gene as the result of a t(9;22) (p24;q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet. 2008;183(2):105–8.

    Article  CAS  PubMed  Google Scholar 

  7. Lane SW, Fairbairn DJ, McCarthy C, Nandini A, Perry-Keene J, Kennedy GA. Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22)(p24;q11.2) leading to BCR-JAK2 fusion. Br J Haematol. 2008;142(4):503.

    Article  PubMed  Google Scholar 

  8. Impera L, Lonoce A, Fanfulla DA, Moreilhon C, Legros L, Raynaud S. Two alternatively spliced 5′BCR/3′JAK2 fusion transcripts in a myeloproliferative neoplasm with a three-way t(9;18;22) (p23;p11.3;q11.2) translocation. Cancer Genet. 2011;204:512–5.

    Article  CAS  PubMed  Google Scholar 

  9. Angelova S, Spassova S, Toshkov S, Shivarov V. Chromosomal translocation t(9;22) (p24;q11) appears to be recurrently associated with myeloid malignancy with aggressive course. Leuk Lymphoma. 2011;52(9):1809–10.

    Article  CAS  PubMed  Google Scholar 

  10. Elnaggar MM, Agersborg S, Sahoo T, Girgin A, Ma W, Rakkhit R, et al. BCR-JAK2 fusion as a result of a translocation (9;22) (p24;q11.2) in a patient with CML-like myeloproliferative disease. Mol Cytogenet. 2012;5(1):23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Xu Y, Yin J, Pan J, Wu C, Wang Q, Yao H, et al. A BCR-JAK2 fusion gene from ins(22;9) (q11;p13p24) in a patient with atypical chronic myeloid leukemia. Leuk Lymphoma. 2013;54(10):2322–4.

    Article  PubMed  Google Scholar 

  12. Bellesso M, Santucci R, Dias DF, Centrone R, Elias RC. Atypical chronic myeloid leukemia with t(9;22) (p24,11.2), a BCR-JAK2 fusion gene. Rev Bras Hematol Hemoter. 2013;35:218–9.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol. 2015;94:233–8.

    Article  CAS  PubMed  Google Scholar 

  14. Tirado CA, Chen W, Huang LJ, Laborde C, Hiemenz MC, Valdez F, et al. Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia. Leuk Res. 2010;34(12):1674–6.

    Article  CAS  PubMed  Google Scholar 

  15. Cuesta-Domínguez Á, Ortega M, Ormazábal C, Santos-Roncero M, Galán-Díez M, Steegmann JL, et al. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase. PLoS One. 2012;7(2):e32451.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153–66.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Chase A, Bryant C, Score J, Haferlach C, Grossmann V, Schwaab J, et al. Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. Haematologica. 2013;98(3):404–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9) (p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood. 2012;120(7):1529–31.

    Article  CAS  PubMed  Google Scholar 

  19. Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013;31(17):e269–71.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bulent Kantarcioglu.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kantarcioglu, B., Kaygusuz-Atagunduz, I., Uzay, A. et al. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature. Int J Hematol 102, 383–387 (2015). https://doi.org/10.1007/s12185-015-1792-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-015-1792-2

Keywords

Navigation